A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

NCT05576974 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Unknown Primary Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pegsitacianine

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]